View Financial HealthRadnostix 배당 및 자사주 매입배당 기준 점검 0/6Radnostix 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.05%자사주 매입 수익률총 주주 수익률-0.05%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.공시 • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States공시 • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.공시 • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.공시 • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.공시 • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.공시 • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.공시 • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.공시 • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.공시 • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 INIS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: INIS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Radnostix 배당 수익률 vs 시장INIS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (INIS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Life Sciences)0.7%분석가 예측 (INIS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 INIS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 INIS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 INIS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: INIS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:15종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Radnostix, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mauro SuarezAlliance Global PartnersDavid Matthew KratochvilAlliance Global Partners
공시 • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.
공시 • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States
공시 • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.
공시 • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.
공시 • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.
공시 • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.
공시 • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.
공시 • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.
공시 • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.
공시 • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.